Inventage Lab

Inventage Lab P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Inventage Lab (389470.KQ) as of Oct 22, 2026 is -54.85. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -80.93 — a change of -32.22% (higher).

P/CF

-54.85

YoY

-32.22%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Inventage Lab is 2025 -54.85 . P/CF (Price-to-Cash-Flow Ratio) of Inventage Lab was 2024 -80.93 . It decreases by -32.22% higher compared to the previous year.

The Inventage Lab P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2019
-390.40 KRW
Jan 1, 2020
-302.49 KRW
Jan 1, 2021
-130.86 KRW
Jan 1, 2022
-214.67 KRW
Jan 1, 2023
-95.12 KRW
Jan 1, 2024
-80.93 KRW
Jan 1, 2025
-54.85 KRW
The Inventage Lab P/CF history
YEARP/CFYoY
-54.85-32.22%
-80.93-14.91%
-95.12-55.69%
-214.67+64.04%
-130.86-56.74%
-302.49-22.52%
-390.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

P/CF (Price-to-Cash-Flow Ratio) of Inventage Lab is -54.85 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Inventage Lab changed from -80.93 to -54.85, representing a -32.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Inventage Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Inventage Lab

All Key Metrics — Inventage Lab